Accordingly, therapeutic antibodies targeting CTLA-4, PD-1, programmed cell death ligand-1(PD-L1), and LAG-3 have been developed to release the brakes imposed by checkpoint receptors in advanced cancers [5–8]. This evidence concerns the gene CD274 and cancer.